Publications by authors named "Stephane Nahon"

Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract where early diagnosis and timely, appropriate management are essential to prevent severe complications and reduce the need for surgery. This review sought to investigate factors contributing to diagnostic delays in CD, which typically ranged from 5 to 16 months. Delays were often due to nonspecific symptoms that could be mistaken for irritable bowel syndrome (IBS) and were influenced by various factors including age, education level, smoking, NSAID use, and disease characteristics like isolated ileal involvement.

View Article and Find Full Text PDF

Background: Appropriate prescription of Proton pump inhibitors (PPIs) remains an important concern amid the rising overuse. A gap exists in the literature regarding the benefit of PPI prophylaxis and the consequences of underprescription in patients at risk for upper gastrointestinal bleeding (UGIB).

Aims: This study aims to describe the characteristics of hemorrhage in relation to PPI use in patients experiencing UGIB, with a focus on high-risk individuals requiring gastroprotection.

View Article and Find Full Text PDF
Article Synopsis
  • Biosimilars like CT-P17 offer cost-effective treatment options for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs about these treatments can impact their adherence to switching.
  • This study involved 232 adult patients who transitioned to CT-P17 from either a low-concentration biosimilar or the reference adalimumab to gauge their treatment satisfaction and experiences over three months.
  • Results showed that satisfaction remained stable overall, but significantly more patients switching from a low-concentration biosimilar reported increased satisfaction compared to those switching from the reference product.
View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted with 941 IBD patients to assess their satisfaction with different adalimumab preparations, including biosimilars and the original brand, Humira.
  • The average satisfaction rating was 8.5 out of 10, with the highest satisfaction observed for Humira and its biosimilars like Hulio and Amgevita, where scores were notably above 8.5.
  • Injection site reactions were reported by 31.8% of patients, and a portion of those previously treated with another adalimumab had discontinued due to side effects; overall, patient satisfaction remained high despite these issues.
View Article and Find Full Text PDF

Background: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied.

Aims: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB.

Methods: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres.

View Article and Find Full Text PDF

Background: The impact of inflammatory bowel disease (IBD) on caregivers has rarely been investigated. Our work aims to explore the burden of IBD on the different aspects of caregivers' lives.

Methods: We conducted an online survey via the social network of the French IBD patient organization addressed to patients' caregivers who were asked to fill in a questionnaire covering the impact of the disease on different aspects of their lives.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the prevalence and incidence of hepatitis E virus (HEV) infection in patients with inflammatory bowel disease (IBD) undergoing immunomodulatory treatment, given that these medications can compromise the immune system.
  • Conducted across 16 French centers, the research involved 488 IBD patients, revealing very few cases of acute HEV infection, with a seroprevalence of 14.2% for chronic infection, particularly among older patients and those with higher seafood intake.
  • The findings suggest that routine HEV screening isn't necessary for IBD patients on immunomodulators, but HEV should be tested if liver abnormalities occur.
View Article and Find Full Text PDF

Introduction: There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails.

Methods: We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events.

View Article and Find Full Text PDF

Background And Aims: There are concerns regarding the potential impact of the COVID-19 outbreak on patients with inflammatory bowel disease [IBD]. We report on the impact of the COVID-19 outbreak in a European prospective cohort study of patients with IBD.

Patients And Methods: We prospectively collected data from 5457 patients with IBD nested in the ongoing I-CARE project and still followed up in April 2020, with monthly online monitoring of clinical activity, treatment, imaging and endoscopy.

View Article and Find Full Text PDF

Background: The exact rate of contraindications to anti-TNF therapy and physician perspectives on treatment choices facing to anti-TNF contraindication, are poorly reported.

Methods: A two-week cross-sectional study was conducted in 31 centres. Physicians completed a questionnaire for a total of 1,314 consecutive outpatients with Crohn's disease, assessing each patient's potential contraindications to anti-TNF therapy, the choice of alternative therapy to anti-TNFs, and their preference in an unrestricted reimbursement setting.

View Article and Find Full Text PDF

Background And Aims: The use of telemedicine dramatically increased during the COVID-19 pandemic. We collected patients and physicians experience on telemedicine in the field of inflammatory bowel disease (IBD).

Methods: We conducted a nationwide survey between September 2020 and January 2021.

View Article and Find Full Text PDF

Background: The prevalence of obesity and the number of bariatric surgeries in both the general population and in patients with inflammatory bowel disease (IBD) have increased significantly in recent years. Due to small sample sizes and the lack of adequate controls, no definite conclusions can be drawn from the available studies on the safety and efficacy of bariatric surgery (BS) in patients with IBD. Our aim was to assess safety, weight loss, and deficiencies in patients with IBD and obesity who underwent BS and compare findings to a control group.

View Article and Find Full Text PDF

 Prognostic and risk factors for upper gastrointestinal bleeding (UGIB) might have changed overtime because of the increased use of direct oral anticoagulants and improved gastroenterological care. This study was undertaken to assess the outcomes of UGIB in light of these new determinants by establishing a new national, multicenter cohort 10 years after the first.  Consecutive outpatients and inpatients with UGIB symptoms consulting at 46 French general hospitals were prospectively included between November 2017 and October 2018.

View Article and Find Full Text PDF

Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available.

Aims: To assess the real-world effectiveness and safety of ustekinumab in patients with UC.

Methods: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included.

View Article and Find Full Text PDF

Background: Up to 25% of patients with ulcerative colitis (UC) will require hospitalization for severe flare. In patients hospitalised for severe flare, who previously experienced multiple drug failures, including steroids and anti-TNF agents, new quick-acting medical options are needed. Tofacitinib is effective in refractory UC and has a rapid onset of action.

View Article and Find Full Text PDF

Background: Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19). In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up.

Methods: In a registry-study which included patients hospitalized for COVID-19 between March 15 and April 2, 2020, we compared patients who received HCQ/AZI to those who did not, regarding a composite outcome of mortality and mechanical ventilation with a 28-days follow-up.

View Article and Find Full Text PDF

Objectives: Patients who develop upper gastrointestinal bleeding (UGIB) while in hospital appear to have a poor prognosis. Our study aims at analysing the difference in outcome between in-patients (IPs) and out-patients presenting with variceal and non-variceal UGIB.

Methods: We conducted a multicentre prospective study by collecting data about variceal and non-variceal UGIB cases through 46 hospitals in France between November 2017 and October 2018.

View Article and Find Full Text PDF

Background: The increased risk of upper gastrointestinal bleeding (UGIB) related to direct oral anticoagulants (DOACs) as compared to vitamin K antagonists (VKA) remains debated.

Aims: To describe the epidemiology and outcomes of UGIB in patients treated with oral anticoagulants.

Methods: A prospective, multicentre study in French general hospitals enrolled all consecutive patients with UGIB during one year.

View Article and Find Full Text PDF

Background: Abdominal or pelvic radiotherapy in inflammatory bowel disease (IBD) patients raises concerns regarding the risk of worsening of underlying disease.

Aim: To assess the impact of radiotherapy on IBD course.

Methods: A retrospective multicentre study including IBD patients exposed to abdominal or pelvic irradiation was conducted, retrieving IBD activity by semester (6-month periods) before (from S-4 to S-1) and after (from S + 1 to S + 6) radiotherapy and IBD flare during follow-up.

View Article and Find Full Text PDF

Aim: To assess the impact of liver function test (LFT) abnormalities on the prognosis of patients with coronavirus disease 2019 (COVID-19) in a French cohort of hospitalized patients.

Patients And Method: From March 13 to April 22, 2020, we collected on a computerized and anonymized database, medical records, laboratory data and clinical outcomes of patients hospitalized for confirmed cases of COVID-19 infection (RT-PCR and/or CT-scan). Patients were followed up until April 22, 2020 or until death or discharge.

View Article and Find Full Text PDF

Background: There are few data concerning patients with Crohn's disease (CD) complicated by a stricture of the upper gastrointestinal tract (UGT).

Aims: We evaluated the outcome and management of CD patients complicated by a stricture of the UGT.

Methods: We performed a retrospective multicenter study including all CD patients with a non-passable symptomatic UGT stricture on endoscopy.

View Article and Find Full Text PDF

Background/aims: Few data on the evolution of endoscopic findings are available in patients with acute severe ulcerative colitis (ASUC). The aim of this study was to describe this evolution in a prospective cohort.

Methods: Patients admitted for a steroid-refractory ASUC and included in a randomized trial comparing infliximab and cyclosporine were eligible if they achieved steroid-free clinical remission at day 98.

View Article and Find Full Text PDF

Background: Crohn's disease (CD) is a chronic disorder requiring long-term treatment. However, up to 20% of patients interrupt temporarily or permanently anti-TNFα. Primary aim was to identify internal and external factors influencing patient's motivation to pursue anti-TNFα in active CD.

View Article and Find Full Text PDF